BioStock: BioInvent comments on breast cancer study progress

BioInvent’s pipeline consists of five drug candidates advancing through six clinical trials. During the San Antonio Breast Cancer Symposium, BioInvent presented the first clinical data from one of these – the phase I/IIa trial of its second FcyRIIB-blocking antibody BI-1607. BioStock reached out to BioInvent’s Chief Medical Officer Andres McAllister for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/bioinvent-comments-on-breast-cancer-study-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/